Literature DB >> 19448400

The expanding realm of prion phenomena in neurodegenerative disease.

Bess Frost1, Marc I Diamond.   

Abstract

The aggregation of a soluble protein into insoluble, beta-sheet rich amyloid fibrils is a defining characteristic of many neurodegenerative diseases, including prion disorders. The prion protein has so far been considered unique because of its infectious nature. Recent investigations, however, suggest that other amyloid-forming proteins associated with much more common diseases, such as tau, alpha-synuclein, amyloid beta and polyglutamine proteins, while not infectious in the classical sense, share certain essential properties with prions that may explain phenotypic diversity, and patterns of spread within the nervous system. We suggest a common mechanism of pathogenesis of myriad sporadic and inherited neurodegenerative diseases based on templated conformational change.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19448400      PMCID: PMC2712602          DOI: 10.4161/pri.3.2.8754

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  31 in total

1.  Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure.

Authors:  M von Bergen; P Friedhoff; J Biernat; J Heberle; E M Mandelkow; E Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  Support for the prion hypothesis for inheritance of a phenotypic trait in yeast.

Authors:  M M Patino; J J Liu; J R Glover; S Lindquist
Journal:  Science       Date:  1996-08-02       Impact factor: 47.728

4.  Lack of the carboxyl terminal sequence of tau in ghost tangles of Alzheimer's disease.

Authors:  R Endoh; M Ogawara; T Iwatsubo; I Nakano; H Mori
Journal:  Brain Res       Date:  1993-01-22       Impact factor: 3.252

5.  Cell-free formation of protease-resistant prion protein.

Authors:  D A Kocisko; J H Come; S A Priola; B Chesebro; G J Raymond; P T Lansbury; B Caughey
Journal:  Nature       Date:  1994-08-11       Impact factor: 49.962

6.  Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice.

Authors:  Lary C Walker; Michael J Callahan; Feng Bian; Robert A Durham; Alex E Roher; William J Lipinski
Journal:  Peptides       Date:  2002-07       Impact factor: 3.750

7.  Propagation of tau misfolding from the outside to the inside of a cell.

Authors:  Bess Frost; Rachel L Jacks; Marc I Diamond
Journal:  J Biol Chem       Date:  2009-03-11       Impact factor: 5.157

8.  Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy.

Authors:  H F Baker; R M Ridley; L W Duchen; T J Crow; C J Bruton
Journal:  Mol Neurobiol       Date:  1994-02       Impact factor: 5.590

9.  Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells.

Authors:  Wen Yang; John R Dunlap; Richard B Andrews; Ronald Wetzel
Journal:  Hum Mol Genet       Date:  2002-11-01       Impact factor: 6.150

10.  Cells release prions in association with exosomes.

Authors:  Benoit Fevrier; Didier Vilette; Fabienne Archer; Damarys Loew; Wolfgang Faigle; Michel Vidal; Hubert Laude; Graça Raposo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

View more
  15 in total

Review 1.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

Review 2.  Corruption and spread of pathogenic proteins in neurodegenerative diseases.

Authors:  Lary C Walker; Harry LeVine
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

3.  An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.

Authors:  Rodrigo A Fuentealba; Jayne Marasa; Marc I Diamond; David Piwnica-Worms; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2011-11-03       Impact factor: 6.150

Review 4.  Network activity changes in the pathophysiology of Alzheimer's disease: the role of aging and early entorhinal cortex dysfunction.

Authors:  Sharay E Setti; Miranda N Reed
Journal:  Metab Brain Dis       Date:  2021-09-30       Impact factor: 3.584

Review 5.  Natural compounds may open new routes to treatment of amyloid diseases.

Authors:  Jan Bieschke
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

6.  Context dependence of protein misfolding and structural strains in neurodegenerative diseases.

Authors:  Anil K Mehta; Rebecca F Rosen; W Seth Childers; John D Gehman; Lary C Walker; David G Lynn
Journal:  Biopolymers       Date:  2013-11       Impact factor: 2.505

7.  Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease.

Authors:  Benjamin J Bell; Medhinee M Malvankar; Carolyn Tallon; Barbara S Slusher
Journal:  ACS Chem Neurosci       Date:  2020-10-13       Impact factor: 4.418

Review 8.  Neuropathology of non-Alzheimer degenerative disorders.

Authors:  Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2009-08-25

9.  Multifaceted roles of tunneling nanotubes in intercellular communication.

Authors:  Ludovica Marzo; Karine Gousset; Chiara Zurzolo
Journal:  Front Physiol       Date:  2012-04-10       Impact factor: 4.566

10.  Comparative Incidence of Conformational, Neurodegenerative Disorders.

Authors:  Jesús de Pedro-Cuesta; Alberto Rábano; Pablo Martínez-Martín; María Ruiz-Tovar; Enrique Alcalde-Cabero; Javier Almazán-Isla; Fuencisla Avellanal; Miguel Calero
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.